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Summary
Background: There are limited and conflicting data on clinical outcomes of community-acquired
pneumonia (CAP) among HIV-infected patients.
Methods: Secondary analyses of clinical outcomes of CAP were performed for 118 patients with
HIV infection and 2790 patients without HIV infection enrolled in the Community-Acquired
Pneumonia Organization (CAPO) international study. After adjustment for significant confoun-
ders, the effect of HIV infection on length of stay (LOS) and time to clinical stability (TCS) were
examined by survival analyses and overall mortality and CAP-related mortality by logistic
regression methods.
Results: After adjusting for significant confounders, hospitalized HIV-infected patients with CAP
did not have longer times to reach clinical stability (HR 1.126; 95% CI 0.917—1.391; p = 0.251) or
longer stays in the hospital (HR 1.191, 95% CI 0.979—1.449; p = 0.080). In addition, HIV infection
did not significantly influence overall mortality rates (OR 1.205, 95% CI 0.686—2.116; p = 0.517) or
CAP-related mortality rates (OR 1.338; 95% CI 0.623—3.725; p = 0.355).
* Corresponding author. Tel.: +1 202 269 7747; fax: +1 202 269 7892.
E-mail address: jmbord01@gwise.louisville.edu (J. Bordon).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2009.03.001
Conclusion: The presence of HIV infection did not influence the clinical outcomes of CAP among
patients assessed at CAPO centers. It is not intended that our results be extrapolated to
populations receiving limited healthcare for advanced HIV disease, malnourishment and parasitic
diseases.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Pulmonary infections are a major cause of morbidity and
mortality in persons infected with HIV.1 Pneumonia due to
unspecified organisms has been reported to be the leading
cause of death among HIV-infected individuals in the USA
during 1990—1999.2 The introduction of highly active anti-
retroviral therapy (HAART) has led to a notable decline in
opportunistic infections (OI), however bacterial pneumonia
remains prevalent.3 In addition, bacterial community-
acquired pneumonia (CAP) has been reported to be a common
cause of hospitalization among HIV-infected patients.4,5
The etiology, risk and prognostic factors of CAP among
hospitalized HIV-infected patients have been examined.
However, studies comparing clinical outcomes of CAP in
patients with and without HIV infection are limited and
results are conflicting. To date, five studies have evaluated
the outcomes of mortality in HIV-infected patients hospita-
lized with CAP.6—10 Higher mortality rates among HIV-
infected subjects were found in three studies.5—7 Four of
these five studies evaluated length of stay (LOS) and one
study found longer LOS among HIV-infected patients. Time to
clinical stability (TCS), as a measurable outcome of CAP, was
defined in a case—control study of 58 HIV patients done by our
group using the Community Acquired Pneumonia Organiza-
tion (CAPO) database. Similar outcomes were found between
HIV-infected patients and those without HIV infection. These
five studies did only univariate analyses of clinical outcomes
of CAP.
Because of these conflicting results, we performed a study
with the objective of evaluating clinical outcomes of bacter-
ial CAP among hospitalized HIV-infected patients using a
cohort design and multivariate analyses that made adjust-
ment for confounders.
Materials and methods
Study design
A secondary analysis was performed of the Community-
Acquired Pneumonia Organization (CAPO) database.11 CAPO
is an international, retrospective, observational study of
adult patients hospitalized with CAP. Data were analyzed
from hospitals in seven countries (USA, Canada, Spain, South
Africa, Argentina, Venezuela, Chile), between June 2001 and
March 2006. In each participating center, random medical
records of hospitalized patients with the diagnosis of CAP
were reviewed. The presence of HIV infection was obtained
from medical history. Each investigator filled out a case
report form that was transferred via the Internet to the
CAPO study center at the University of Louisville, KY, USA.
A sample of the data collection form is available at the study
website (www.caposite.com). Validation of data quality was
performed at the study center before the case was entered inthe CAPO database. Antibiotic therapy for CAP was examined
following each country’s guidelines and categorized as: (1)
compliance if empirical therapy covered expected CAP bac-
teria, and (2) non-compliance if antibiotic treatment did not
cover expected CAP bacteria.
Inclusion criteria
Patients who were included in the study met the following
criteria for the diagnosis of CAP: (1) new pulmonary infiltrate
on a chest radiograph, and (2) at least one of the following:
(a) a new or worse cough, (b) an abnormal body temperature
(<35.6 8C or >37.8 8C), and/or (c) an abnormal serum leu-
kocyte count.
Exclusion criteria
In an attempt to limit our investigation to bacterial CAP,
patients with a presumptive or definitive diagnosis of Pneu-
mocystis pneumonia (PCP), mycobacterial and fungal pneu-
monia were excluded from this study. Furthermore, patients
were excluded if they were treated for a suspected PCP,
mycobacterial or fungal etiology.
Study groups
Two study groups were established, the group of CAP patients
with HIV infection based on the presence of positive serology
for HIV antibody and a second group categorized as CAP
patients without HIV infection based on the presence of
negative HIV antibody or unknown HIV status.
Study outcomes
Time to clinical stability (TCS)
A patient was defined as clinically stable and ready to be
switched to an oral antibiotic the day that the following four
criteria were met: (1) improved cough and shortness of
breath, (2) lack of fever for at least 8 hours, (3) improving
leukocytosis (decreased at least 10% from the previous day),
and (4) tolerating oral intake with adequate gastrointestinal
absorption.12 Patients were evaluated daily within the first
seven days of hospitalization to determine the day when
clinical stability was reached.
Length of stay (LOS)
Defined in days and calculated for each patient as the day of
discharge minus the day of admission. Patients hospitalized
for more than 14 days were censored at 15 days in an effort to
capture LOS data related only to bacterial CAP.
All-cause mortality
The sum of all patients with a final clinical outcome classified
as dead. The final clinical outcome ‘death or alive’ was
e24 M. Malinis et al.evaluated at time of hospital discharge. The final clinical
outcome for patients who were still hospitalized at day 28
was considered as alive.
CAP-related mortality
Patients in whom the cause of death was considered to be
directly related to CAP, due to progression of infection with
development of severe sepsis and/or metastatic foci as
determined by the local investigator.
Confounding variables
The following 28 variables were obtained from each study
participant. Demographics: age, gender, and nursing home
residency. Coexisting conditions: neoplastic disease, chronic
obstructive pulmonary disease (COPD), diabetes mellitus,Table 1 Baseline patient characteristics stratified by HIV status
Variables Patients with HIV
infection (n = 118)
Mean age 40
Males (%) 87 (74%)
ICU admission 14 (12%)
Mean PSI 50
Risk class
I 38 (32%)
II 36 (30%)
III 23 (19%)
IV 15 (13%)
V 6 (5%)
CRB-65 0.35
0 81 (69%)
1 32 (27%)
2 5 (4%)
3 0 (0%)
4 0 (0%)
Chronic morbidities
Cancer 3 (2%)
Renal disease 9 (8%)
Liver disease 17 (14%)
Cerebrovascular accident 2 (2%)
Congestive heart failure 4 (3%)
COPD 13 (11%)
Diabetes mellitus 8 (7%)
Alcohol/drug use 37 (31%)
Chest X-ray
Multilobar infiltrate 40 (34%)
Cavitary lesion 0 (0%)
Pleural effusion 11 (9%)
Time to first antibiotic, hours 7.3
ICU, intensive care unit; PSI, pneumonia severity index; CRB-65, confu
mmHg or diastolic blood pressure 60 mmHg and 65 years of age; C
a A p-value of< 0.05 was considered statistically significant. p-Values
the independent samples t-test, while p-values for categorical variab
Whitney test or Fisher’s exact test where appropriate.renal disease, liver disease, alcohol and/or illegal drug
use, cerebrovascular accident (CVA), and congestive heart
failure (CHF). Physical examination: temperature, respira-
tory rate, heart rate, blood pressure, and altered mental
status. Laboratory tests: sodium, arterial partial pressure of
O2, hematocrit, blood urea nitrogen, glucose, and arterial
pH. Chest X-ray: multilobar involvement, presence of cavity,
and presence of pleural effusion. Severity of CAP: need for
ICU admission, risk class according to the pneumonia severity
index (PSI), and CRB-65 score.13,14
Statistical analysis
Differences in continuous baseline characteristics between
patients with HIV infection and without HIV infection were
compared by means of unpaired t-tests. Baseline categoricalPatients without HIV
infection (n = 2790)
p-Valuea
67 <0.0001
1710 (61%) 0.0065
343 (12%) 0.890
93 <0.0001
226 (8%) <0.0001
422 (15%) 0.0175
606 (22%) 0.5621
1067 (38%) <0.0001
469 (17%) 0.0072
0.95 <0.0001
907 (32%) <0.0001
1249 (45%) 0.0002
524 (19%) <0.0001
93 (3%) 0.0438
17 (1%) 0.3951
279 (10%) 0.007
318 (11%) 0.327
101 (4%) <0.001
453 (16%) <0.001
588 (21%) <0.001
836 (30%) <0.001
548 (20%) <0.001
231 (8%) <0.001
820 (29%) 0.014
32 (1%) 0.205
566 (20%) 0.001
6.6 0.240
sion, respiratory rate >30 per minute, systolic blood pressure <90
OPD, chronic obstructive pulmonary disease.
for continuous variables were calculated by comparing means using
les were calculated using the Chi-square test, Wilcoxon—Mann—
Table 3 Logistic regression model investigating the influ-
ence each variable has on overall mortality when adjusting
for all other confounders
Variable p-Value OR 95% CI of the OR
Age 0.282 1.009 0.992—1.027
Male gender 0.093 1.408 0.944—2.099
Liver disease 0.983 0.990 0.413—2.373
Cancer 0.019 0.421 0.205—0.865
Nursing home 0.005 4.534 1.561—13.169
Multilobar infiltrates <0.001 2.522 1.713—3.714
HIV infection 0.517 1.205 0.686—2.116
PSI <0.001 1.022 1.014—1.030
CRB-65 class 1 0.023 3.100 1.168—8.230
CRB-65 class 2 0.008 4.165 1.460—11.877
CRB-65 class 3 <0.001 14.211 4.400—45.898
CRB-65 class 4 <0.001 39.239 7.340—209.766
OR, odds ratio; CI, confidence interval; PSI, pneumonia severity
index; CRB-65, confusion, respiratory rate >30 per minute,
systolic blood pressure <90 mmHg or diastolic blood pressure
60 mmHg and 65 years of age.
Table 4 Logistic regression model investigating the influ-
ence each confounder has on CAP-related mortality when
adjusting for all other confounders
Variable p-Value OR 95% CI of the OR
Age 0.150 1.010 0.997—1.023
Male gender 0.115 1.289 0.940—1.767
Liver disease 0.014 0.585 0.350—0.889
Cancer 0.048 2.855 1.114—3.743
Nursing home 0.193 0.656 0.318—1.520
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percentages, and differences between both groups of
patients were analyzed using a Chi-square test, the Wil-
coxon—Mann—Whitney test, and Fisher’s exact test when
appropriate and warranted. Since mortality was dichoto-
mized in this study, we examined the association between
HIV infection and mortality using a logistic regression model.
We then incorporated all standard risk factors into the model
by utilizing multiple logistic regression analyses. A stepwise
procedure was then employed to obtain the final model. LOS
and TCS were analyzed with the Kaplan—Meier method,
whereas log-rank tests and Cox proportional-hazards regres-
sion analyses were applied to evaluate differences between
both groups of patients. In our analyses, LOS was truncated at
14 days and TCS was truncated at 7 days. The Breslow—Day
test was performed to evaluate possible heterogeneities of
the effect of HIV infection on outcomes according to the
country of residence and it demonstrated that the groups
were sufficiently homogenous, providing justification for the
pooled analyses performed.
Results
Clinical outcomes of CAP were examined in 118 patients with
HIV infection and2790patientswithoutHIV infection. Baseline
characteristics of both groups of patients are illustrated in
Table 1. Patients with HIV infection were younger and pre-
dominantly male. Patients with HIV infection had less severe
CAP and patients without HIV infection had significantly
greater rates of co-morbidities,except for liver illness.Alcohol
and drug abuse were present in approximately a third (31%) of
HIV-infected patients, around four times more often than in
those without HIV infection (8%). Positive bacterial cultures
were present in 43 (36%) of the infected patients. Strepto-
coccus pneumoniae was the most common isolated organism
and it accounted for 75% of the etiology of pneumonia. A total
of 54 (46%) HIV-infected patients had determinations of CD4+
cell count. The CD4+ cell counts ranged from 4 to 1074/mm3
and a count >200/mm3 was present in 57% of patients. Com-
pliance with the local country’s guidelines for antibiotic ther-
apy for CAP was 89.8% and 87.6% among individuals with and
without HIV infection, respectively.
The rates of all-cause mortality and CAP-related mortal-
ity were not influenced by the HIV status before adjusting for
confounders (Table 2). Similarly, the logistic regression
model indicated that HIV status does not have a significant
effect on all-causemortality (OR 1.205, 95% CI 0.686—2.116;
p = 0.517) when adjusted for other confounders (Table 3). In
addition, HIV infection was eliminated in the stepwise selec-
tion and excluded from the final model. The saturatedTable 2 Comparison of mortality rates by HIV status before
adjustment for confounders
Mortality HIV-infected Non-HIV-infected p-Value
All-cause
mortality
9.8% 9.2% 0.3128
CAP-related
mortality
5.0% 4.4% 0.5492
CAP, community-acquired pneumonia.logistic regression analysis for CAP-related mortality is
shown in Table 4. These results also indicate that HIV infec-
tion does not have a significant effect on CAP-related mor-
tality (OR 1.338; 95% CI 0.623—3.725; p = 0.355).
The Kaplan—Meier survival analysis for TCS stratified by
HIV status suggests that HIV-infected patients have a shorter
TCS (Chi-square 12.26; p < 0.001). However, HIV infection
did not have significant influence on TCS (HR 1.126, 95% CI
0.917—1.391; p = 0.251) after the adjustment for confoun-
ders in the Cox regression analysis (Table 5). Similarly, the
Kaplan—Meier survival analysis for LOS stratified by HIV status
showed that HIV-infected individuals had a shorter LOS (Chi-
square 15.85; p < 0.001), while the Cox regression analysis
showed that HIV infection does not have significant influence
on LOS (HR 1.191, 95% CI 0.979—1.449; p = 0.080) (Table 6).Multilobar infiltrates 0.098 0.708 0.529—1.055
HIV infection 0.355 1.338 0.623—3.725
PSI <0.001 1.014 1.007—1.020
CRB-65 class 1 0.078 4.622 0.983—6.521
CRB-65 class 2 0.298 2.386 0.875—4.567
CRB-65 class 3 0.381 2.046 0.824—6.237
CRB-65 class 4 0.265 2.542 0.426—14.897
CAP, community-acquired pneumonia; OR, odds ratio; CI, confi-
dence interval; PSI, pneumonia severity index; CRB-65, confusion,
respiratory rate>30perminute, systolicbloodpressure<90mmHg
or diastolic blood pressure 60 mmHg and 65 years of age.
Table 5 Cox regression model for time to clinical stability
(TCS)
Variable p-Value HR 95% CI of the HR
Age 0.001 1.007 1.003—1.010
Male gender <0.001 0.843 0.768—0.927
Liver disease 0.199 0.970 0.817—1.151
Cancer 0.628 0.848 0.659—1.091
Nursing home 0.128 0.834 0.661—1.054
Multilobar infiltrate 0.028 0.892 0.806—0.988
HIV infection 0.251 1.126 0.917—1.391
PSI <0.001 0.996 0.993—0.996
CRB-65 class 1 <0.001 0.794 0.703—0.897
CRB-65 class 2 <0.001 0.655 0.550—0.781
CRB-65 class 3 <0.001 0.377 0.248—0.571
CRB-65 class 4 0.020 0.189 0.046—0.771
HR, hazards ratio; CI, confidence interval; PSI, pneumonia sever-
ity index; CRB-65, confusion, respiratory rate >30 per minute,
systolic blood pressure<90 mmHg or diastolic blood pressure60
mmHg and 65 years of age.
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Our study indicates that clinical outcomes of CAP among
hospitalized HIV-infected patients are similar to those with-
out HIV infection among CAPO centers in the USA, Europe,
South Africa and South America. That is, patients with HIV
infection and patients without HIV infection had similar time
to clinical stability, length of stay, all-cause mortality, and
CAP-related mortality rates in the multivariable Cox regres-
sion and the multiple logistic regression analyses. In compar-
ison with previous studies, our results were adjusted for
confounders.
Upon initial assessment, patients with HIV infection had
lower PSI scores than patients without HIV infection. This
implies that physicians had a low threshold for admission of
HIV-infected patients with CAP, likely because of the pre-
sumption that HIV-infected patients have worse outcomes
than patients without HIV infection. National organizations
from several countries have developed guidelines for theTable 6 Cox regression model for length of stay (LOS)
Variable p-Value HR 95% CI of the HR
Age 0.008 1.004 1.001—1.008
Male gender 0.083 0.927 0.851—1.010
Liver disease 0.296 1.083 0.932—1.259
Cancer 0.239 0.874 0.699—1.093
Nursing home 0.430 1.080 0.892—1.306
Multilobar infiltrate 0.008 0.883 0.806—0.969
HIV infection 0.080 1.191 0.979—1.449
PSI <0.001 0.995 0.993—0.996
CRB-65 class 1 0.012 0.866 0.775—0.968
CRB-65 class 2 <0.001 0.742 0.635—0.868
CRB-65 class 3 0.998 1.000 0.752—1.330
CRB-65 class 4 0.028 2.022 1.077—3.795
HR, hazards ratio; CI, confidence interval; PSI, pneumonia sever-
ity index; CRB-65, confusion, respiratory rate >30 per minute,management of patients with CAP. Most guidelines, however,
have excluded HIV-infected patients due to the paucity of
data regarding management decisions such as need for hos-
pitalization, timing to switch to oral therapy and hospital
discharge.12 One important implication of our study results is
that several of themanagement recommendations offered by
national guidelines can be safely applied to HIV-infected
patients with CAP. The presence of HIV infection by itself
should not be considered a risk factor for poor clinical out-
comes and should not alter important management decisions
such as site of care, timing for oral switch, or criteria for
hospital discharge. Our study showed that the increasing
severity of pneumonia measured by CRB-65 and PSI deter-
mines the outcomes of CAP patients regardless of the status
of HIV infection.
Studies that have examined CAP among hospitalized HIV-
infected patients have reported conflicting clinical out-
comes. HIV-infected patients were found to have higher
mortality rates in four studies.6—8,15 Park et al. reported
high rates of homelessness, tobacco smoking, and intrave-
nous drug use among HIV-infected patients.6 Thus, these
results may not be generalized to the entire population of
HIV-infected patients. In addition, none of these patients was
taking HAART. The International Pneumococcal Study Group
has recently examined the outcome of bacteremic pneumo-
coccal pneumonia in a cohort of 200 HIV-infected patients.15
HIV-infected patients had greater mortality than those with-
out HIV infection. The HIV-infected patients were predomi-
nantly from South Africa and had median CD4+ cell counts of
119/mm3. Touchie and Marrie enrolled 32 HIV-infected
patients with a mean CD4+ cell count of 70  98.5/mm3
and 50% of CAP etiology was PCP.7 The low CD4+ cell count
and high incidence of PCP indicate advanced immunosuppres-
sion, which could explain the higher mortality rate among
HIV-infected patients than among HIV-uninfected patients.
Johnson et al. included mainly subjects with CD4+ cell counts
<200/mm3 (74%) and did not describe the etiology of pneu-
monia.8 HIV-infected patients are expected to have poor CAP
outcomes in settings with endemic malnourishment and
recurrent parasitic diseases receiving limited healthcare.
In comparison to these studies, our study examined a cohort
of HIV-infected patients with less advanced immunosuppres-
sion with proven and presumed bacterial CAP after the
exclusion of PCP, tuberculosis and fungal pneumonia.
Similar LOS seen in both our groups of patients has also
been reported by others.7,9,10 Johnson et al. found longer LOS
among HIV-infected patients. This could be explained by the
same reasons cited for higher mortality rates in the group of
HIV-infected patients.8 TCS directly correlates with length of
hospitalization. It is defined by the time a patient is con-
sidered stable enough to be switched from intravenous to
oral antibiotic therapy as defined by Ramirez et al.16
Although it has been reported in several studies, TCS has
not been well defined among HIV-infected patients with CAP.
Our group is the first to compare the TCS in relation to CAP
between hospitalized HIV-infected patients and patients
without HIV infection. After adjusting for confounders, the
results of our study proved that the TCS between the two
groups of patients was equivalent.
It is recognized that patients with HIV infection are at
increased risk of developing bacterial CAP. An HIV patient
with two episodes of S. pneumoniae CAP meets criteria for
Outcomes of HIV-infected patients with bacterial CAP e27AIDS.17 The increased risk of S. pneumoniae CAP is primarily
related to abnormalities of T-cells and immunoglobulins. The
pulmonary host defenses are initiated and coordinated by
alveolar macrophages in bacterial CAP. Gordon et al. found a
similar ability of alveolar macrophages to attach and phago-
cytize opsonized pneumococci in HIV-positive and negative
patients.18 These data suggest that alveolar macrophages of
HIV-infected patients maintain the ability to kill CAP-related
bacteria. Even though HIV-infected patients are at increased
risk of developing bacterial CAP, laboratory data and clinical
data of this study suggest that the host response to bacteria is
similar regardless of the HIV status. Similarly to previous
studies, incomplete data for CD4+ cell counts, HIV-RNA levels
and HAART are limitations of our study.
We acknowledge that our study has important limitations.
It is limited by the nature of a retrospective design, incom-
plete CD4+ cell count data, and lack of information regarding
prophylaxis for opportunistic infections, HAART, and prior
vaccination status. Confirmation of etiology of pneumonia
was unknown in 66% of our patients, a rate higher than the
rate of 26—35% reported by other studies.6,7,9 Lastly, even
though our patients are from countries with low prevalence
of HIV infection, the numbers of HIV-infected patients might
also be underestimated since HIV testing is not done in all
hospitalized patients with CAP enrolled in the CAPO study.
Conversely, a major strength of our study is the utilization of
multivariate techniques to adjust potential confounders for
more precisely measuring the impact of HIV infection on
outcomes. In view of limitations of the current literature,
future studies of HIV-infected individuals with bacterial CAP
should include complete data of CD4+ cell counts, HIV-RNA
levels, HAART intake and HAART adherence.
In summary, our study indicates that the presence of HIV
infection does not influence the clinical outcomes of patients
with CAP after adjustment for confounders. It is not intended
that these results be extrapolated to populations receiving
limited healthcare for advanced HIV disease, malnourish-
ment and parasitic diseases. The decision regarding initial
site of care for an HIV-infected patient with CAP should be
based on the patient’s severity of disease and not influenced
by the presence of HIV infection. Our study suggests that
several strategies recommended by national organizations
for the management of non-immunocompromised patients
with CAP may be safely used to manage HIV-infected patients
with bacterial CAP.
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